Excision BioTherapeutics KOL Webinar on HIV and the Ongoing Phase 1/2 Trial Evaluating Excision’s CRISPR-Based Therapy EBT-101 as a Potential Cure
About The Event
Join us for a key opinion leader (KOL) event with Excision BioTherapeutics, featuring Daniel Kuritzkes, MD (Brigham and Women’s Hospital) and Nicole Paulk, PhD (UCSF Department of Biochemistry and Biophysics).
During the event, the KOLs and members of the Excision leadership team will provide an overview of its CRISPR-based technology platform designed to address viral infectious diseases, an update on the ongoing Phase 1/2 trial evaluating EBT-101 as a potential cure for HIV, and a discussion on the current treatment landscape and unmet needs of people living with HIV. EBT-101 is a unique, in vivo CRISPR-based therapeutic designed to cure HIV infections with a single treatment by removing HIV proviral DNA from infected cells. Excision’s pipeline unites next-generation CRISPR nucleases with a novel gene editing approach to develop curative therapies for Herpes Virus, JC Virus, which causes PML, and Hepatitis B virus.
A live Q&A session will follow the formal presentations.